Ritu Nayar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ritu Nayar has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
Diane Davis Davey
Department of Clinical Sciences University of Central Florida Orlando Florida
5 shared publicationsRobert Goulart
New England Pathology Associates, Trinity Health of New England, Springfield, Massachusetts
5 shared publications- Xiaoqi Lin
Department of Pathology Feinberg School of Medicine, Northwestern University Chicago Illinois USA
4 shared publications David C. Wilbur
Departments of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
3 shared publicationsDenise V. S. DeFrias
Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois
3 shared publications- Jeffrey F. Krane
David Geffen School of Medicine at UCLA
3 shared publications
Latest Publications
- 30 January 2026
- Published by Wolters Kluwer Health in Journal of Lower Genital Tract Disease
- Vol. 30 (2) , 97-99
Re: Self-Collected Vaginal Specimens at Home for HPV Testing: Recommendations From the Enduring Guidelines Committee
- 30 January 2026
- Published by Wolters Kluwer Health in Journal of Lower Genital Tract Disease
- Vol. 30 (2) , 97-99
Re: Self-Collected Vaginal Specimens at Home for HPV Testing: Recommendations From the Enduring Guidelines Committee
- Top Cited PapersOpen Access
- 10 January 2025
- Published by Wolters Kluwer Health in Journal of Lower Genital Tract Disease
- Vol. 29 (2) , 134-143
Applying Results of Extended Genotyping to Management of Positive Cervicovaginal Human Papillomavirus Test Results: Enduring Guidelines
Objective: The Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee developed recommendations for the use of extended genotyping results in cervical cancer prevention programs. Methods: Risks of cervical intraepithelial neoplasia grade 3 or worse were calculated using data obtained with the Onclarity HPV Assay from large cohorts. Management recommendations were based on clinical action thresholds developed for the 2019 American Society for Colposcopy and Cervical Pathology Risk-Based Management Consensus Guidelines. Risk estimates were reviewed in relation to clinical action thresholds and used as the basis for draft recommendations. After an open comment period, recommendations were finalized and ratified through a vote by the Consensus Stakeholder Group. Results: Colposcopy is recommended after positive tests for human papillomavirus (HPV) types 16 and 18. For those positive for HPV 45, 33/58, 31, 52, 35/39/68, or 51 but negative for 16 or 18, triage with cytology or dual stain testing is recommended. When screening with primary HPV testing, for patients who test positive for HPV types 56/59/66 and no other carcinogenic types, repeat HPV testing in 1 year is recommended. When screening with cotesting, for those who test positive for HPV types 56/59/66 and no other carcinogenic types, 1-year return is recommended for negative for intraepithelial lesion or malignancy, atypical squamous cells of undetermined significance, and low-grade squamous intraepithelial lesion, and colposcopy is recommended for atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion (ASC-H), atypical glandular cells, high-grade squamous intraepithelial lesion, or carcinoma. When patients without prior high-grade cytology (atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion, atypical glandular cells, high-grade squamous intraepithelial lesion, or carcinoma) or histology (cervical intraepithelial neoplasia [CIN]2, CIN3, or adenocarcinoma in situ) are being followed, use of extended genotyping results is acceptable. When high-grade cytology or histology results are present, or when patients are being followed after treatment of CIN2+, management using the 2019 guidelines is recommended. Conclusions: Human papillomavirus extended genotyping can guide clinical management in the setting of a positive HPV test result.
- 10 January 2025
- Published by Wolters Kluwer Health in Journal of Lower Genital Tract Disease
- Vol. 29 (2) , 134-143
Top Cited PapersOpen AccessApplying Results of Extended Genotyping to Management of Positive Cervicovaginal Human Papillomavirus Test Results: Enduring Guidelines
Objective: The Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee developed recommendations for the use of extended genotyping results in cervical cancer prevention programs. Methods: Risks of cervical intraepithelial neoplasia grade 3 or worse were calculated using data obtained with the Onclarity HPV Assay from large cohorts. Management recommendations were based on clinical action thresholds developed for the 2019 American Society for Colposcopy and Cervical Pathology Risk-Based Management Consensus Guidelines. Risk estimates were reviewed in relation to clinical action thresholds and used as the basis for draft recommendations. After an open comment period, recommendations were finalized and ratified through a vote by the Consensus Stakeholder Group. Results: Colposcopy is recommended after positive tests for human papillomavirus (HPV) types 16 and 18. For those positive for HPV 45, 33/58, 31, 52, 35/39/68, or 51 but negative for 16 or 18, triage with cytology or dual stain testing is recommended. When screening with primary HPV testing, for patients who test positive for HPV types 56/59/66 and no other carcinogenic types, repeat HPV testing in 1 year is recommended. When screening with cotesting, for those who test positive for HPV types 56/59/66 and no other carcinogenic types, 1-year return is recommended for negative for intraepithelial lesion or malignancy, atypical squamous cells of undetermined significance, and low-grade squamous intraepithelial lesion, and colposcopy is recommended for atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion (ASC-H), atypical glandular cells, high-grade squamous intraepithelial lesion, or carcinoma. When patients without prior high-grade cytology (atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion, atypical glandular cells, high-grade squamous intraepithelial lesion, or carcinoma) or histology (cervical intraepithelial neoplasia [CIN]2, CIN3, or adenocarcinoma in situ) are being followed, use of extended genotyping results is acceptable. When high-grade cytology or histology results are present, or when patients are being followed after treatment of CIN2+, management using the 2019 guidelines is recommended. Conclusions: Human papillomavirus extended genotyping can guide clinical management in the setting of a positive HPV test result.
- 2 August 2023
- Published by Springer Nature
- p. C1
Correction to: Atypia of Undetermined Significance
- Open Access
- 9 September 2021
- Published by MDPI AG in Journal of Molecular Pathology
- Vol. 2 (3) , 274-280
Precision Prevention: The 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors
The approach to cervical cancer prevention has evolved significantly over the past two decades. HPV immunization has decreased the specificity of screening modalities and HPV-based testing has been replacing our previously successful morphology-only approach. Additionally, there is much more emphasis on providing precision prevention, rather than the previously used “one-fits-all” management strategies. A number of new biomarkers are entering clinical practice and being integrated into cervical cancer screening and management in order to enable a more personalized assessment of the risk for precancer/cancer for an individual patient. The 2019 ASCCP Risk-Based Management Consensus Guidelines expand on the concept of “equal management for equal risk”. They consider a patient’s history in addition to current test results to provide recommendations for increased surveillance/treatment in patients at higher risk for CIN3+ while minimizing interventions for lower-risk patients who have new versus persistent HPV infection. Clinical management decisions are based on immediate risk and 5-year risk estimates for CIN3+, which are determined by referencing an extensive risk table compiled by the National Cancer Institute (NCI). The course of action for a given patient is recommended by comparison of the risk in the risk database, to the predetermined clinical action thresholds. These guidelines address the need for simplification and offer some stability for the provider while being conducive to the incorporation of anticipated continued technologic advances in methods for cervical cancer prevention. Their enduring nature will allow for changes needed based on risk reduction as HPV vaccination uptake increases and vaccinated women reach screening age. Similarly, the design allows for the addition of new tests into the risk assessment calculations after their approval by applicable regulatory agencies and review/consensus approval by the ASCCP new technology and enduring guidelines workgroups. As cytopathologists, we must be familiar with the scientific advancements in primary and secondary prevention, evolving screening and management guidelines, and participate actively in the multidisciplinary approach for the prevention of cervical cancer.
- 9 September 2021
- Published by MDPI AG in Journal of Molecular Pathology
- Vol. 2 (3) , 274-280
Open AccessPrecision Prevention: The 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors
The approach to cervical cancer prevention has evolved significantly over the past two decades. HPV immunization has decreased the specificity of screening modalities and HPV-based testing has been replacing our previously successful morphology-only approach. Additionally, there is much more emphasis on providing precision prevention, rather than the previously used “one-fits-all” management strategies. A number of new biomarkers are entering clinical practice and being integrated into cervical cancer screening and management in order to enable a more personalized assessment of the risk for precancer/cancer for an individual patient. The 2019 ASCCP Risk-Based Management Consensus Guidelines expand on the concept of “equal management for equal risk”. They consider a patient’s history in addition to current test results to provide recommendations for increased surveillance/treatment in patients at higher risk for CIN3+ while minimizing interventions for lower-risk patients who have new versus persistent HPV infection. Clinical management decisions are based on immediate risk and 5-year risk estimates for CIN3+, which are determined by referencing an extensive risk table compiled by the National Cancer Institute (NCI). The course of action for a given patient is recommended by comparison of the risk in the risk database, to the predetermined clinical action thresholds. These guidelines address the need for simplification and offer some stability for the provider while being conducive to the incorporation of anticipated continued technologic advances in methods for cervical cancer prevention. Their enduring nature will allow for changes needed based on risk reduction as HPV vaccination uptake increases and vaccinated women reach screening age. Similarly, the design allows for the addition of new tests into the risk assessment calculations after their approval by applicable regulatory agencies and review/consensus approval by the ASCCP new technology and enduring guidelines workgroups. As cytopathologists, we must be familiar with the scientific advancements in primary and secondary prevention, evolving screening and management guidelines, and participate actively in the multidisciplinary approach for the prevention of cervical cancer.
- 1 September 2021
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 10 (5) , 445-446
FOREWORD: JASC special issue on education in cytopathology
- 1 September 2021
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 10 (5) , 445-446
FOREWORD: JASC special issue on education in cytopathology
- Open Access
- 1 September 2021
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 10 (5) , 447-458
Harmonization of training, training program requirements, board certification, and the practice of cytopathology: data from the American Board of Pathology surveys
- 1 September 2021
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 10 (5) , 447-458
Open AccessHarmonization of training, training program requirements, board certification, and the practice of cytopathology: data from the American Board of Pathology surveys
- 1 September 2021
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 10 (5) , 485-494
ACGME Milestones 2.0: why and what’s new for cytopathology?
- 1 September 2021
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 10 (5) , 485-494
ACGME Milestones 2.0: why and what’s new for cytopathology?
- 1 July 2020
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 9 (4) , 291-303
Moving forward—the 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors and beyond: implications and suggestions for laboratories
- 1 July 2020
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 9 (4) , 291-303
Moving forward—the 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors and beyond: implications and suggestions for laboratories